IMCR Earnings Prediction
The chart below shows how IMCR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, IMCR sees a +0.05% change in stock price 10 days leading up to the earnings, and a -5.45% change 10 days following the report. On the earnings day itself, the stock moves by +1.09%. This data can give you a slight idea of what to expect for the next quarter's release.
IMCR Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
84.05M
19.80%
4.74%
Gross Margin
99.61%
-0.10%
0.17%
Operating Margin
-23.14%
-4.77%
118.51%
Net Margin
-28.28%
0.57%
-359.69%
EPS
-0.47
-17.50%
-376.47%
No Data Available
IMCR Earnings Analysis
Immunocore Holdings PLC Corporation (IMCR.O) Earnings Conference Call
Positive
Total Revenue Growth: KIMMTRAK achieved $310 million in total revenue for 2024, representing a 30% year-on-year growth.
Net Revenue Increase: In Q4 2024, KIMMTRAK generated $84.1 million in net revenues, a 5% increase from Q3 2024.
KIMMTRAK Market Growth: The U.S. market for KIMMTRAK grew at an impressive 34% year-on-year, accounting for $226 million of total sales.
KIMMTRAK Global Expansion: KIMMTRAK has been launched in 14 new countries in 2024, bringing the total to 39 countries, including recent approvals in Brazil, the U.K., and Poland.
Phase III Trial Advancements: The company has advanced three ongoing Phase III trials, including the TEBE-AM and ATPM trials, and randomized the first patient in the PRISM-MEL trial.
Clinical Pipeline Expansion: Immunocore initiated two Phase I trials with novel molecules in 2024, expanding its clinical pipeline.
New Therapeutic Areas Exploration: The company is exploring new therapeutic areas, including autoimmune diseases, with two candidates targeting type 1 diabetes and atopic dermatitis.
Strong Cash Position: Immunocore has a strong cash position of $820 million at the end of 2024, allowing for continued investment in R&D and commercial activities.
Negative
Reimbursement Challenges in Europe: KIMMTRAK's reimbursement environment in Europe remains challenging, impacting revenue recognition estimates.
Increased R&D Investments: R&D expenses increased significantly due to investments in three Phase III trials, indicating a heavy reliance on ongoing clinical development.
Increased SG&A Expenses: SG&A expenses have also increased, reflecting the need for more general business functions to support operations, which could strain financial resources.
Revenue Growth Challenges: Despite a strong year in sales, the company faces pressure to maintain growth in 2025, with expectations of only incremental revenue growth from KIMMTRAK.
Clinical Trials Uncertainty: The company is still in the early stages of several clinical trials, which introduces uncertainty regarding future outcomes and timelines for new product launches.
IMCR FAQs
How does IMCR typically perform around its earnings report dates?
Is Immunocore Holdings PLC (IMCR) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
IMCR Earning Call Sentiment
Immunocore Holdings plc (IMCR) Q4 2024 Earnings Call Transcript
IMCR.O
0.3%Positive
Despite increased R&D expenses and competition, the company showed strong revenue growth (30% YoY), a solid cash position, and successful loan repayment. The Q&A highlighted ongoing developments and market penetration, with analysts showing interest in future prospects. The company's financial health and optimistic guidance, along with a market cap under $2 billion, suggest a positive stock price movement.
